Logo Image
|Articles|January 30, 2023

Sulbactam-Durlobactam Granted Priority Review With China’s Medical Regulatory Body

The investigational therapy developed by Entasis is indicated for treatment of Acinetobacter baumannii.

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted sulbactam-durlobactam (SUL-DUR) a priority review status for a New Drug Application (NDA) for the treatment of infections caused by Acinetobacter baumannii, including multidrug-resistant and carbapenem-resistant (CRAB) strains.

SUL-DUR is an intravenous investigational drug developed by Entasis Therapeutics. The therapy is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV β-lactamase inhibitor, or BLI, being developed for the treatment of infections caused by ABC, including multidrug and carbapenem-resistant strains.

Entasis granted Zai Lab Zai Lab an exclusive license to develop and commercialize SUL-DUR in Greater China (mainland China, Hong Kong, Taiwan and Macau), Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand and Japan.

“The CDE’s decision to grant priority review to our NDA for SUL-DUR underscores the importance of addressing the urgent need for new treatment options for patients with life-threatening infections caused by Acinetobacter species including multidrug and carbapenem-resistant strains,” Harald Reinhart, MD, president and head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, Zai Lab, said in a statement. “CRAB infections are among the worst bacterial infections, and safe and effective treatment options are limited. We thank the agency for their commitment and continued support to patients in need and look forward to working closely with them to advance this important therapy toward approval in China, where CRAB infections are still frequently seen in ICUs and result in high mortality rates.”

No specific date has been offered in the NDA information. SUL-DUR has been designated a Qualified Infectious Disease Product by the US FDA, a designation that aims to spur development of new antibiotics for difficult-to-treat infections. The FDA has accepted the SUL-DUR NDA for priority review with an action date of May 29, 2023.

Related to this article

View more
Ceftriaxone Safety: Separating Signal From Risk
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Read more
Treatment of Latent Tuberculosis in a Trice
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Read more
Drawing Borders Around a Borderless Specialty
Drawing Borders Around a Borderless Specialty
Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Read more
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.
Read more
A Review of Vibrio vulnificus: Clinical Presentation and Treatment
A Review of Vibrio vulnificus: Clinical Presentation and Treatment
Vibrio species are bacteria that live in saltwater environments. When ingested orally or through contact with open wounds, some species can cause severe life-threatening infections, particularly in those with high-risk conditions, such as liver disease. Here is a review of Vibrio vulnificus and the recommended antibiotic treatment.
Read more